Author(s): Williams J, Sayles HR, Meza JL, Sayre P, Sandkovsky U, , Williams J, Sayles HR, Meza JL, Sayre P, Sandkovsky U,
Abstract Share this page
Abstract AIM: To gauge patient interest in receiving long-acting injectable nanoformulated antiretroviral therapy. METHODS: Four hundred adult HIV-infected patients currently prescribed antiretroviral therapy were surveyed. χ(2) tests were used for comparisons of interest across groups. RESULTS: Respondents were 68\% male and 53\% African-American, with a mean age of 47 years. Overall, 73\% of patients indicated that they would definitely or probably try injectable nanoformulated antiretroviral therapy; 61\% with weekly dosing; 72\% every 2 weekly; and 84\% monthly. In total, 48\% indicated that they were very concerned about the possible side effects and 35\% were very concerned about needle use. CONCLUSION: The majority of respondents indicated that they definitely or probably would try parenteral nanoformulated antiretroviral therapy.
This article was published in Nanomedicine (Lond)
and referenced in Journal of AIDS & Clinical Research